Quarterly report pursuant to Section 13 or 15(d)

DEVELOPMENT AWARDS (Details Narrative)

v3.21.1
DEVELOPMENT AWARDS (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended 36 Months Ended
May 31, 2019
Mar. 31, 2019
Mar. 31, 2021
Dec. 31, 2020
Mar. 31, 2020
Sep. 30, 2020
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2020
Jan. 26, 2018
Entity Listings [Line Items]                      
Revenue     $ 647,824   $ 1,762,059            
CFF Warrant [Member]                      
Entity Listings [Line Items]                      
Warrant exercisable price per share     $ 13.20                
Cystic Fibrosis Foundation [Member]                      
Entity Listings [Line Items]                      
Payments for royalty $ 2,700,000                    
Collaboration and License Agreement [Member] | Kaken Pharmaceutical Co., Ltd. [Member]                      
Entity Listings [Line Items]                      
Upfront payment, received from related party   $ 27,000,000                  
Consideration receivable on milestone payments   $ 173,000,000                  
Royalty term description   The “Royalty Term” means the period beginning on the date of the first commercial sale of the Licensed Product in Japan and ends on the latest of (i) the expiration of the last valid claim of the royalty patents covering such Licensed Product in Japan, (ii) the expiration of regulatory exclusivity for such Licensed Product for such Initial Indication in Japan, or (iii) ten (10) years after the first commercial sale of such Licensed Product for such Initial Indication in Japan. The Agreement may be terminated by either party for material breach, upon a party’s insolvency or bankruptcy or upon a challenge by one party of any patents of the other party, and Kaken may terminate in specified situations, including for a safety concern or clinical failure, or at its convenience following the second anniversary of the first commercial sale of a Licensed Product in either of the Initial Indications in the Territory, with 180 days’ notice.                  
Revenue from related parties, recorded as deferred revenue   $ 27,000,000                  
Contract with Customer, Liability, Revenue Recognized       $ 27,000,000              
Royalty payable 27,000,000                    
Cystic Fibrosis Program Related Investment Agreement [Member] | Phase 2b Clinical Trial [Member]                      
Entity Listings [Line Items]                      
Royalty payable 2,700,000                    
Payments for royalty $ 27,000,000                    
Proceeds from investments on achieving milestones           $ 22,500,000          
Loans Payable     $ 2,500,000                
Cystic Fibrosis Program Related Investment Agreement [Member] | Maximum [Member]                      
Entity Listings [Line Items]                      
Gain Contingency, Unrecorded Amount                     $ 25,000,000
Investment Agreement [Member] | 2018 CFF Award [Member]                      
Entity Listings [Line Items]                      
Revenue     $ 647,824   $ 1,762,059            
Investment Agreement [Member] | CFF Warrant [Member]                      
Entity Listings [Line Items]                      
Warrant to purchase of common stock     1,000,000                
Warrant exercisable price per share     $ 9.46                
Warrants expiration term       Jan. 26, 2025     Jan. 26, 2025     Jan. 26, 2025  
Investment Agreement [Member] | CFF Warrant [Member] | Immediately Exercisable Warrants [Member]                      
Entity Listings [Line Items]                      
Warrant to purchase of common stock     500,000                
Investment Agreement [Member] | CFF Warrant [Member] | Warrants Exercisable On Completion Of Final Milestone [Member]                      
Entity Listings [Line Items]                      
Warrant to purchase of common stock     500,000                
Investment Agreement [Member]                      
Entity Listings [Line Items]                      
Revenue     $ 0       $ 5,000,000 $ 5,000,000 $ 12,500,000 $ 22,500,000  
Contract asset     2,266,000       $ 1,618,000        
Investment Agreement [Member] | Cystic Fibrosis Foundation Warrants [Member]                      
Entity Listings [Line Items]                      
Revenue     25,000,000                
Additional paid in capital, fair value of warrant issued     6,215,225                
Revenue to be recognized     $ 18,784,775